echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Long-lasting wrinkle removal!

    Long-lasting wrinkle removal!

    • Last Update: 2022-06-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 21, Eastern Time, Revance Therapeutics announced that its Biologics License Application (BLA) for DaxibotulinumtoxinA for injection in the treatment of moderate to severe frown lines has been accepted by the U.


    Moderate to severe glabellar lines This is a long-acting neuromodulator for aesthetic and multiple potential therapeutic indications Long-acting neuromodulator

    DaxibotulinumtoxinA (RT002) is a novel, next-generation, long-acting neuromodulator based on Revance's proprietary technology platform.


    A novel, next-generation, long-acting neuromodulator based on Revance's proprietary technology platform,

    Research has shown that RT002 can be used for cosmetic and treatment of symptoms including glabellar lines, cervical dystonia and plantar fasciitis


    The product works by blocking nerve impulses, temporarily inhibiting muscle movements that cause wrinkles, resulting in smoother, refreshed skin.


    According to data published in 2021 in the Official Journal of the American Society for Dermatologic Surgery (ASDS) , subjects experienced rapid and sustained improvement in the severity of static glabellar lines after repeated treatment with RT002


    After repeated treatment with RT002, subjects experienced rapid and sustained improvement in the severity of static glabellar lines


    In China, Fosun Pharma's holding subsidiary Fosun Pharma Industry signed a license agreement with Revance in December 2018 to introduce RT002 for exclusive use, import, sales and other commercialization (excluding manufacturing) in mainland China, Hong Kong and Macau.


    Authorized application areas include cosmetic and therapeutic indications

    Screenshot source: Official website of China Drug Clinical Trial Registration and Information Publicity Platform

    According to the official website of the China Drug Clinical Trial Registration and Information Publicity Platform, RT002 is conducting two international multi-center Phase 3 studies in China, namely: 1) To evaluate the efficacy and Safety: A randomized, double-blind, placebo-controlled, parallel, international multicenter Phase 3 study in China Extension Study (ASPEN-1-CN); 2) To evaluate the efficacy and safety of RT002 in the treatment of moderate to severe glabellar lines : A multicenter, randomized, double-blind, placebo-controlled phase 3 clinical study


    China Extension Study of International Multicenter Phase 3 Study

    It is hoped that RT002 will progress smoothly in clinical development and registration application, and bring long-acting therapy to patients as soon as possible


    References:

    References:

    [1] Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines .


    [3] Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery .


    [4] Fu Rui Medical Technology (1696.
    HK) entered into a sublicense agreement with Fosun Industrial on the long-acting botulinum toxin product RT002.
    Retrieved Jul 15, 2021, from https://mp.
    weixin.
    qq.
    com/s/StHq29UDGmHPBFTEhNG8Ew
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.